Technology
Health
Pharmaceutical

Spero Therapeutics

$10.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (1.11%) As of 11:50 AM EDT today
+$0.11 (1.11%) Today

Why Robinhood?

You can buy or sell SPRO and other stocks, options, ETFs, and crypto commission-free!

About SPRO

Spero Therapeutics, Inc. Common Stock, also called Spero Therapeutics, is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Read More Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Employees
41
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
171.96M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
51.87K
High Today
$10.23
Low Today
$9.78
Open Price
$10.00
Volume
9.62K
52 Week High
$14.48
52 Week Low
$5.52

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2017 IPO
US

SPRO Earnings

Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.